Oklahoma is suing 3 major opioid manufacturers for their role in the opioid epidemic; first responders and other workers exposed to carcinogens during 9/11 found to have an elevated incidence of leukemia; cost of MS treatments determine patient financial decisions.
Oklahoma State Attorney General Mike Hunter filed a lawsuit on Monday against 3 companies, McKesson Corporation, Cardinal Health, and AmerisourceBergen, who delivered more than 34 billion doses of narcotics to Oklahoma and the rest of the United States between 2006 and 2012, according to The Washington Post. “To say these companies have blood on their hands is an understatement,” said Hunter. The case alleges the companies failed to halt plainly suspicious drug orders due to the profits generated from these transactions.
In a study conducted by New York researchers, first responders and other workers at the World Trade Center site after the September 11, 2001, terrorist attacks were found to have an elevated incidence of leukemia compared with the general population. The Wall Street Journal reports that the findings also suggest that as more time passes from the attacks, researchers may discover increased rates of other cancers in first responders and recovery workers.
According to a survey by the National Multiple Sclerosis (MS) Society, the high cost of MS treatments has forced 40% of patients to take drastic actions, such as cutting back or skipping doses, and affected their ability to save for the future. STAT reports that 14% of survey participants switched to a generic, despite being satisfied with their existing treatment; 12% stopped using their medication for a period of time; 9% skipped or delayed filling a prescription; and 8% took less of their medicine than prescribed. Compared with 2004, when patients with MS paid an average $15/month out of pocket, in 2016, they doled out $309/month, which is more than a 20-fold increase in just 12 years.
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma
March 7th 2024The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Read More
Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care
October 13th 2021On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive® who talks with the advance practice provider chief at Winship Cancer Institute about how having a dedicated cancer urgent care center will make cancer treatment plans seamless whil helping patients avoid exposure to infectious diseases in emergency department waiting rooms.
Listen
ICYMI: Highlights From ASH 2023
December 20th 2023The most-read content from the 2023 American Society of Hematology Annual Meeting and Exposition included the latest in treating hematologic malignancies, the hope brought by novel therapy strategies, and the potential for artificial intelligence to improve diagnostic accuracy.
Read More
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
December 11th 2023Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Read More